Viewray: Compelling Early Pancreatic Cancer Data with ViewRay’s MRIdian System Presented at ESTRO 36

Date: Friday, 25 August 2017

Presentations Also Highlighted Speed and Benefit of On-Table Adaptive Therapy in Routine Clinical Use May 15, 2017

CLEVELAND, May 15, 2017 — ViewRay, Inc. (Nasdaq: VRAY) announced today highlights from ESTRO 36, the annual meeting of the European Society for Radiotherapy and Oncology, which featured broad clinical experience with the company’s MRIdian System, including compelling early data on its use in pancreatic cancer.

Pancreatic Cancer

A presentation by Sasa Mutic, Ph.D., from Washington University School of Medicine in St. Louis, highlighted early retrospective multi-institutional data on pancreatic cancer treatments with MRIdian at University of California, Los Angeles (UCLA) Health System; University of Wisconsin Carbone Cancer Center; VU University Medical Center; and Washington University School of Medicine. The study compared SBRT treatments with and without on-table adaptive dose reshaping and found that delivering a higher biological dose, enabled by MRI-guided on-table adaptive radiotherapy, may lead to improved survival in locally advanced pancreatic cancer.

A second clinical presentation on pancreatic cancer treatment with MRIdian was given by Anna Bruynzeel, M.D., Ph.D., from VU University Medical Center, focusing on their single-institutional experience. Early results illustrated MRIdian’s ability to deliver high doses with low toxicity, despite the proximity of the duodenum, through the use of daily plan adaptation and real-time tracking.

Following the promising data presented at ESTRO, ViewRay plans to support a multi-institutional single-arm prospective clinical trial in unresectable pancreatic cancer to demonstrate the benefits of MRIdian’s daily on-table adaptive SBRT and real-time tissue tracking capabilities, with a focus on toxicity, local control and overall survival outcomes.

Watch the video